Sacubitril-d4

Sacubitril-d4 is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

Product Specifications

CAS Number

[1884269-07-1]

Product Name Alternative

AHU-377-d4

UNSPSC

12352005

Hazard Statement

H301, H400

Target

Neprilysin

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

98.54

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C[C@H](C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(C([2H])(C([2H])(C(O)=O)[2H])[2H])=O)C(OCC)=O

Molecular Formula

C24H25D4NO5

Molecular Weight

415.52

Precautions

H301, H400

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38 (10) :1689-700.|[3]Voors AA, et al. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22 (8) :1041-7.|[4]von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8 (1) :71-8.